NEK2 and mesothelioma: The same clinical implication of high NEK2A expression is also observed in other cancers, including acute myeloid leukemia, bladder cancer, breast cancer, glioma, lung adenocarcinoma, mantle cell lymphoma, and mesothelioma [12].